cervical cancer
Conditions
Interventions
Use a treatment containing zimberelimab group:NA
Sponsors
The First Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
Female
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Patients treated with immunotherapy containing zimberelimab (either monotherapy or in combination) 2) Cervical cancer confirmed by pathology, whether adenocarcinoma, squamous cell carcinoma or adenocarcinoma; 3) Patients with late initial treatment or relapse after treatment; 4) Age =18 years old; 5) Regardless of PD-L1 expression;
Exclusion criteria
Exclusion criteria: 1) No tumor efficacy evaluation; 2) There is central nervous system metastasis;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| diease control rate; | — |
Countries
China
Contacts
Public ContactQiuhong TIan
The First Affiliated Hospital of Nanchang University
Outcome results
None listed